NCT05153434View on ClinicalTrials.gov

A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

May 27, 2022

Primary Completion Date

September 24, 2024

Study Completion Date

September 24, 2024

Conditions
Prader-Willi Syndrome
Interventions
DRUG

ARD-101

Twice Daily, Oral Administration

Trial Locations (2)

80045

Children's Hospital Colorado, Aurora

94304

Stanford University, Palo Alto

Sponsors
All Listed Sponsors
collaborator

Children's Hospital Colorado

OTHER

collaborator

Stanford University

OTHER

lead

Aardvark Therapeutics, Inc.

INDUSTRY